...
首页> 外文期刊>Psychometrika >Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx
【24h】

Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx

机译:荟萃分析的因果推断和多级数据结构,应用于Vioxx的随机研究

获取原文
获取原文并翻译 | 示例

摘要

We construct a framework for meta-analysis and other multi-level data structures that codifies the sources of heterogeneity between studies or settings in treatment effects and examines their implications for analyses. The key idea is to consider, for each of the treatments under investigation, the subject's potential outcome in each study or setting were he to receive that treatment. We consider four sources of heterogeneity: (1) response inconsistency, whereby a subject's response to a given treatment would vary across different studies or settings, (2) the grouping of nonequivalent treatments, where two or more treatments are grouped and treated as a single treatment under the incorrect assumption that a subject's responses to the different treatments would be identical, (3) nonignorable treatment assignment, and (4) response-related variability in the composition of subjects in different studies or settings. We then examine how these sources affect heterogeneity/homogeneity of conditional and unconditional treatment effects. To illustrate the utility of our approach, we re-analyze individual participant data from 29 randomized placebo-controlled studies on the cardiovascular risk of Vioxx, a Cox-2 selective nonsteroidal anti-inflammatory drug approved by the FDA in 1999 for the management of pain and withdrawn from the market in 2004.
机译:我们构建了元分析的框架和其他多级数据结构,这些结构编写了治疗效果的研究或环境之间的异质性源,并检查了它们对分析的影响。关键的想法是考虑对正在调查的每个治疗中,每个研究或环境中受试者的潜在结果是他接受该治疗。我们考虑四种异质性:(1)响应不一致,由此受试者对给定治疗的响应在不同的研究或环境中会有所不同,(2)非异种治疗的分组,其中分组两种或更多种治疗并将其作为单一的处理受试者对不同治疗的反应不正确的假设处理是相同的,(3)非无知治疗分配,(4)不同研究或环境中受试者组成的响应相关的可变性。然后,我们研究这些来源如何影响条件和无条件治疗效果的异质性/均匀性。为了说明我们的方法的效用,我们重新分析了来自29种随机安慰剂对照研究的个人参与者数据,了解了Vioxx的心血管风险,1999年通过FDA批准的COX-2选择性非甾体抗炎药进行疼痛的管理从2004年推出市场。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号